LMND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lemonade Inc (LMND) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company shows strong revenue growth and a growing customer base, its financial performance remains weak with significant net losses and declining EPS. Technical indicators do not suggest a clear upward trend, and insider selling activity raises concerns. Additionally, the options data and trading sentiment do not indicate strong bullish momentum. It is advisable to hold off on purchasing this stock until there is a clearer path to profitability or stronger bullish signals.
The MACD histogram is negative at -1.644, suggesting bearish momentum, though it is contracting. RSI is neutral at 35.837, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot point of 60.539, with key support at 50.393 and resistance at 70.685. Overall, the technical indicators do not signal a strong buy opportunity.
Lemonade achieved record revenue of $738 million in 2025, a 40% YoY increase.
The customer base grew by 23% YoY, reaching nearly 3 million policyholders by the end of
Analysts note Lemonade's digital-first approach and AI-driven efficiencies as structural advantages.
Insiders are selling, with a 136.02% increase in selling activity over the last month.
Analysts express concerns about the company's ability to achieve growth and profitability targets amid competition.
Financials show a significant net loss of -$21.7 million in Q4 2025, with EPS declining by 30.95% YoY.
In Q4 2025, revenue increased by 53.29% YoY to $228.1 million, showcasing strong top-line growth. However, net income dropped to -$21.7 million, a decline of 27.67% YoY, and EPS fell to -0.29, down 30.95% YoY. Gross margin remained at 0%, indicating no improvement in profitability.
Analysts are mixed on LMND. Keefe Bruyette maintains an Underperform rating with a $44 price target, citing challenges in achieving growth and profitability. Piper Sandler lowered its price target to $65 but remains Neutral, while Truist initiated coverage with a Buy rating and a $98 price target, highlighting Lemonade's AI-driven efficiencies. The consensus reflects skepticism about short-term profitability but optimism about long-term potential.
